Clinical Development

Clinical development of varoglutamstat

Phase 1 – Completed

Phase 2a SAPHIR – Completed

Phase 2b VIVIAD – EU Study, Ongoing

Phase 2a/b VIVA-MIND – US Study, Ongoing

Safety and tolerability in 205 healthy volunteers

Varoglutamstat is well-tolerated

Link to

Safety and tolerability in 120 patients with early AD

3-month treatment significantly improved working memory (One Back Test) and synaptic function (EEG), as well as neuroinflammation (CSF Biomarkers)

Link to

Safety, tolerability and efficacy in 250 Patients MCI and mild AD

Endpoints: safety, attention/ working memory, NTB, biomarkers

Link to

Efficacy and safety in 414 patients with early AD

Endpoints: safety, attention/ working memory, CDR-SB biomarkers

Initial Phase 2a in 180 patients with stage-gate to Phase 2b with additional 234 patients